English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We undertook genetic and biochemical assays in patients with arterial (n = 146) and venous (n = 199) thromboembolism and survivors of pulmonary embolism (n = 58) to study causation and gene-life style interactions. In the clinical material from North Western Russia,  factor V Leiden  was found to be a risk factor in venous thrombosis (OR = 3.6), while the methylenetetrahydrofolate reductase  (MTHFR) C677T  mutation was a significant variable in both venous (p = 0.03) and arterial thrombosis (p = 0.004). Homocysteine levels were determined (n = 84) and hyperhomocysteinemia correlated with the  T  allele of the  MTHFR  gene, and with smoking and coffee consumption. Vitamin supplementation reduced homocysteine levels dependent on  MTHFR  genotype (36% TT, 25% CT, 22% CC). In pulmonary embolism patients, frequency of the − 455G/A  β- fibrinogen  dimorphism was studied. Carriers of this allele were significantly underrepresented (p &lt; 0.02) among pulmonary embolism survivors (34.5%) compared to controls (56.7%). Additionally, − 455AA homozygotes  were found in 11.7% controls but only 1.7% of pulmonary embolism patients (p = 0.006). In venous and arterial thrombosis cases,  MTHFR  and homocysteine data led to effective dietary supplementation with a reduced risk of disease progression. Results from the pulmonary embolism study may indicate that screening tests for the − 455G/A  β- fibrinogen  genetic variation could be of prognostic value, and may point the way for novel anticoagulation strategies.

Genetic Variations Observed in Arterial and Venous Thromboembolism – Relevance for Therapy, Risk Prevention and Prognosis